Division of Infectious Disease

Department of Medicine

(DECEMBER 15, 2021) A WCAX-TV Channel 3 (CBS) news story, titled "Team of UVM researchers on cusp of vaccine trials to eliminate polio," features interviews with Larner College of Medicine faculty members Jessica Crothers, M.D., assistant professor of pathology and laboratory medicine, and E. Ross Colgate, Ph.D., M.P.H., assistant professor of microbiology and molecular genetics.

Mitchell Wolfe, M.D., M.P.H., chief medical officer for the Centers for Disease Control and Prevention (CDC) and a Class of 1995 Larner alum, returned to campus for a personal visit on December 13 for the first time since receiving his medical degree here 26 years ago.

Despite a record number of over 400 million cases in 2019, vaccine development for the mosquito-borne dengue virus has been challenging due to the need to protect equally against all four dengue strains. The discovery of new possible biomarkers to predict clinical and immune responses to dengue virus infection could be critical to informing future vaccines.

The University of Vermont Graduate College has announced that Beth Kirkpatrick, M.D., professor and chair of microbiology and molecular genetics, has been named one or three 2021-2022 University Scholars. The University Scholars program recognizes distinguished UVM faculty members for sustained excellence in research, scholarship, and creative arts.

On March 18, 2021, researchers from across UVM came together via Zoom for the second edition of the Translational Global Infectious Diseases Research Center's COVID-19 research slam, titled “UVM Tackles COVID-19: Research Progress and Perspectives One Year into the Pandemic.”

One of the most alarming realizations of the past year has been the clear link between structural racism in the U.S. and the racial and ethnic health disparities that have led to a disproportionate impact of COVID-19 on communities of color. Thanks to the collaboration of numerous partners in Vermont, members of the New American community are getting the education they need to make informed decisions about their health and the COVID-19 vaccine.

A new study conducted by a team of health economists and public health faculty at the University of Vermont suggests that the behavior public officials are now mandating or recommending to slow the spread of COVID-19--wearing a face covering--should come with a caveat. If not accompanied by proper public education, the practice could lead to more infections.

The UVM Medical Center and Vaccine Testing Center have successfully reached and surpassed the targeted number of enrollees for an ongoing Phase 3 clinical trial of the AstraZeneca COVID-19 vaccine.

An internationally recognized physician-scientist, Beth Kirkpatrick, M.D., has a decades-long history of leadership in the field of vaccine testing and development. In 2001, she launched the UVM Vaccine Testing Center (VTC), and since then, the VTC has grown to assume a prominent role in the development and evaluation of vaccines for globally important infectious diseases. The VTC has garnered support from the National Institutes of Health, the Bill & Melinda Gates Foundation, and the U.S. Department of Defense, among others. Kirkpatrick is also principal investigator and director of UVM’s Translational Global Infectious Disease Research Center of Biomedical Research Excellence and Chair of the Department of Microbiology and Molecular Genetics.

The University of Vermont Medical Center and Vaccine Testing Center at the University of Vermont’s Larner College of Medicine have been selected to take part in a Phase 3 trial for a COVID-19 vaccine developed by Oxford University and manufactured by AstraZeneca.

New research, published in Clinical and Translational Immunology by UVM Associate Professor Sean Diehl, Ph.D., and colleagues provides a clearer picture of the protective antibodies induced by the SARS-C0V-2 virus and their role in serious illness and what’s needed for full protection.

New research, published by scientists at the University of Vermont and Caltech in the journal Cell, has pinpointed three specific mechanisms that allow SARS-CoV-2 to incapacitate human cells by disabling the cell’s alarm system to call for help or warn nearby cells of infection.

A team of scientists at the University of Vermont, working in partnership with a group at the University of Washington, has developed a method of testing for the COVID-19 virus that doesn’t make use of these chemicals but still delivers an accurate result, paving the way for inexpensive, widely available testing in both developing countries and industrialized nations like the United States, where reagent supplies are again in short supply.

The University of Vermont received $181.7 million in research funding during the 2020 fiscal year - the largest in UVM history by a wide margin. The Larner College of Medicine had the largest number of grants.

(JULY 29, 2020) Comments from Chair and Professor of Microbiology and Molecular Genetics Beth Kirkpatrick, M.D., were featured in a July 29 article, titled "One Man's Quest to Infect People With Covid-19 for Science," in Elemental, a new Medium publication for science-backed health and wellness coverage.

(JULY 10-20, 2020) Significant national and international media coverage was generated in response to the publication of a Pediatrics Commentary, titled “COVID-19 Transmission and Children: The Child Is Not to Blame,” authored by Assistant Professor of Pediatrics Benjamin Lee, M.D., and Professor of Pediatrics and Director of Pediatric Infectious Diseases William Raszka, M.D.

A commentary published in the journal Pediatrics by Benjamin Lee, M.D. and William V. Raszka, Jr., M.D., concludes that children infrequently transmit COVID-19 to each other or to adults and that many schools, provided they follow appropriate social distancing guidelines and take into account rates of transmission in their community, can and should reopen in the fall.

(JUNE 19 & 24, 2020) Beth Kirkpatrick, M.D., chair of microbiology and molecular genetics and director of the Vaccine Testing Center, was quoted in two ABCNews.com stories - one on a potential COVID-19 vaccine and the other on the durability of COVID-19 antibodies.

University of Vermont scientists, physicians, and students gathered at the Larner College of Medicine February 6 for the first-ever on-campus “virus slam” hosted by the Translational Global Infectious Diseases Research Center. At the event, some twenty experts, from five UVM colleges and institutes, gave five-minute mini-talks that ranged from explaining the biochemistry of the virus’ interaction with the human immune system to interpreting the latest data from the World Health Organization.

The Larner College of Medicine's fourth annual "Celebrating Excellence in Research" series featured two days of presentations and recognition designed to highlight research performed by junior faculty, senior faculty, postdoctoral trainees, and graduate students at the College.